Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results the second quarter ended June 30, 2013.
Net loss for the second quarter was $411,000, or $0.05 per diluted share. Results for the second quarter included financial loss of approximately $304,000 that resulted from the valuation of Tikcro's holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment.
Help employers find you! Check out all the jobs and post your resume.
Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results the second quarter ended June 30, 2013.
Net loss for the second quarter was $411,000, or $0.05 per diluted share. Results for the second quarter included financial loss of approximately $304,000 that resulted from the valuation of Tikcro's holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment.
Help employers find you! Check out all the jobs and post your resume.
